Sheffield Bio-Science and
Wockhardt Ltd. have formed a global sales, marketing and development alliance under which Sheffield will be the exclusive global sales and distribution partner for recombinant insulin manufactured by Wockhardt. Wockhardt was one of the first companies to have developed, manufactured and marketed Wosulin, recombinant insulin injectables. The company’s biotech park in Aurangabad, India has six dedicated manufacturing facilities.
Dr. Habil Khorakiwala, chairman of Wockhardt Group, said, “This partnership is a reaffirmation of Wockhardt’s biotechnology research prowess and a confluence of innovative novel technology now being offered to global cell culture markets.”
Sheffield’s director of global business development, Hans Huttinga, stated, “We are looking forward to developing a strong and lasting partnership between our organizations.”